EI
CLSD

EAM Investors’s Clearside Biomedical CLSD Stock Holding History

EAM Investors’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-16,504
Closed -$1.49M – 296
2021
Q3 		$1.49M Hold
16,504
– – 0.25% 203
2021
Q2 		$1.21M Buy
+16,504
New +$767K 0.19% 275
2018
Q2 		– Sell
-19,941
Closed -$3.21M – 299
2018
Q1 		$3.21M Buy
+19,941
New +$2.43M 0.53% 60

Other funds holding CLSD

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM Investors's CLSD Position: Q4 2021 in Review

EAM Investors sold out of Clearside Biomedical (CLSD) in Q4 2021, closing a stake of 16,504 shares — an estimated $1.49M sold.

EAM Investors first reported a position in CLSD in Q1 2018 and held it in 3 quarters. The position peaked at $3.21M in Q1 2018. 67 funds tracked by Wall St. Rank hold CLSD as of Q4 2021.

  • EAM Investors reported no remaining Clearside Biomedical position as of Q4 2021 after selling out during the quarter.
  • EAM Investors sold 16,504 Clearside Biomedical shares in Q4 2021, an estimated $1.49M.
  • EAM Investors first reported a position in Clearside Biomedical in Q1 2018 and held it in 3 quarters.
  • EAM Investors's Clearside Biomedical position peaked at $3.21M in Q1 2018.
  • 67 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2021.

Based on EAM Investors's 13F filing for Q4 2021, filed 11 Feb 2022.